Atrium Therapeutics, Inc. (RNA) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

Atrium Therapeutics, Inc. (RNA) Company Statistics | The Fly

Atrium Therapeutics, Inc.

· RNA

Dashboard

Financials

Ratios

Valuation

Statistics

144.03 M

-1.66%

General

Market Cap: $144.03M
Enterprise Value: $70.67M
Shares Outstanding: —
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: 98.63%
Operating Margin: -769.30%
Net Profit Margin: -720.90%
FCF Margin: -604.33%
ROA: -33.22%
ROE: -42.90%
ROIC: -38.39%
Current Ratio: 8.73
Debt-to-Equity: 0.01
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: —
P/S: 3.94
P/FCF: —
P/B: 0.66
EV/EBITDA: -0.74

Growth

Rev 1Y: 70.85%
Rev 1Y Fwd Est: 84.60%
Rev 3Y (CAGR): 26.38%
Rev 5Y (CAGR): 22.36%
Rev 10Y (CAGR): —
EPS 1Y: —
EPS 1Y Fwd Est: —
EPS 3Y (CAGR): —

Income Statement (TTM)

Revenue: $35.97M
Gross Margin: 98.63%
Operating Expenses: $312.22M
Operating Income: -$276.74M
Net Profit: -$259.33M

Balance Sheet

EPS 5Y (CAGR)

—

EPS 10Y (CAGR)

—

Cash and Equivalents: $72.65M
Working Capital: $243.54M
Total Assets: $280.51M
Net Debt: -$70.96M
Total Liabilities: $65.94M
Total Equity: $214.58M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$210.49M
Cash Flow from Investing: -$782.49M
Cash Flow from Financing: $1.17B
Free Cash Flow: -$217.39M
Capital Expenditures: $6.9M